Noble and Aptar Pharma have launched AdhereIT – a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home.
AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms. This launch is an important advancement for Noble, an Aptar Pharma company, whose mission is to foster healthy outcomes for patients who self-administer their therapies, partnering with pharma and biotech companies to provide robust training devices and onboarding programs.
AdhereIT Connected Onboarding Platform
Adherence to prescribed biologics is a significant challenge. A recent report in the Journal of the American Academy of Dermatology reported that 45% of studied patients suffering from psoriasis discontinue their treatments. The reasons include insufficient training or time with an instructor, lack of confidence during the self-injection process, and feelings of high anxiety and lack of control. COVID-19 has contributed to the increase utilization of telemedicine and remote healthcare, which has even further complicated this challenge by reducing healthcare professional (HCP) training opportunities with patients.
AdhereIT is part of the digital ecosystem that enables patients to gain control and confidence over their at-home drug delivery while easing the anxiety associated with self-injecting. AdhereIT integrates with the existing software applications developed by the Digital Healthcare team at Aptar Pharma by pairing a patient’s autoinjector via Bluetooth technology to their mobile phone. The device – available in two design options to accommodate dexterity for a one-handed or two-handed injection process – precisely detects an injection event and provides real-time visual, audio and haptic feedback about whether the injection was performed correctly. The AdhereIT on boarding platform also allows HCPs to monitor their patients’ therapeutic performance via a smart analytical dashboard, providing valuable patient-specific adherence behaviour information.
“We are excited to welcome Noble’s AdhereIT connected onoarding platform into the suite of Aptar Pharma’s Digital Healthcare solutions. This innovative technology further enhances our ability to improve patients’ lives by creating a seamless integration of injectable products into our disease management offerings,” said Adam Shain, director of Business Development for Digital Healthcare, Aptar Pharma.
Connected device solutions
Noble developed AdhereIT in partnership with Aptar Pharma, who has made significant investments in digital healthcare over the past three years to actively develop a portfolio of disease management platforms and connected device solutions across dermal, pulmonary, nasal, ophthalmic and injectable routes of administration.
“Connected medical devices represent the future of healthcare for patients, pharmaceutical companies, health insurers and HCPs, playing a vital role in the remote tracking and treatment of chronic illnesses, and delivering a range of benefits that include improved drug management, enriched patient experiences and enhanced patient outcomes,” said Tim McLeroy, Noble’s executive director of Marketing & Patient Services. “The connectivity of digital technology solutions like AdhereIT also create market differentiation and enable value-based contracting for biopharmaceutical companies and medical device manufacturers to survive in a competitive and challenging marketplace.”